Improving tolerability of pembrolizumab with weight based dosing: A meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.2639
Abstract: 2639 Background: Pembrolizumab, a PD-1 immune checkpoint inhibitor (ICI), has demonstrated significant clinical activity in various cancers. Despite a favorable toxicity profile, discontinuation due to adverse events including immune related adverse events (irAE) has been… read more here.
Keywords: discontinuation rate; rate; tolerability pembrolizumab; discontinuation ... See more keywords